JAGX Earnings Prediction
The chart below shows how JAGX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, JAGX sees a -6.71% change in stock price 10 days leading up to the earnings, and a -32.12% change 10 days following the report. On the earnings day itself, the stock moves by -8.00%. This data can give you a slight idea of what to expect for the next quarter's release.
JAGX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
3.11M
10.49%
14.22%
Gross Margin
82.59%
1.05%
-2.04%
Operating Margin
-233.66%
-25.20%
-11.66%
Net Margin
-322.43%
14.75%
-8.88%
EPS
-1.05
-95.33%
-74.01%
No Data Available
JAGX Earnings Analysis
Jaguar Health, Inc. Corporation (JAGX.O) Earnings Conference Call
Positive
Revenue Increase Analysis: 1. Revenue Growth: Jaguar Health reported net revenue of approximately $3.1 million for Q3 2024, marking a 14% increase from Q2 2024 and an 11% increase compared to Q3 2023.
Prescription Volume Increase: 2. Increased Prescription Volume: Mytesi prescription volume rose by 10.9% in Q3 2024 compared to Q2 2024, and increased by 2.7% compared to Q3 2023.
Clinical Trial Presentation Success: 3. Successful Clinical Trial Presentation: The results from the Phase III OnTarget trial's breast cancer subgroup analysis have been accepted for presentation at the prestigious San Antonio Breast Cancer Symposium, highlighting significant clinical signals.
New Product Launch: 4. Launch of New Product: Jaguar successfully launched Gelclair, an FDA-approved oral mucositis prescription product, expanding its commercial offerings and addressing a significant patient need.
Orphan Drug Designation Achieved: 5. Orphan Drug Designation: Crofelemer has received orphan drug designation for both microvillus inclusion disease and short bowel syndrome with intestinal failure, facilitating potential early patient access in Europe.
Negative
Rising Net Loss: 1. Increased Net Loss: Net loss attributable to common shareholders rose by approximately $2.1 million, from $7.8 million in Q3 2023 to $9.9 million in Q3 2024.
Declining Non-GAAP EBITDA Loss: 2. Declining Non-GAAP EBITDA: Non-GAAP recurring EBITDA showed a net loss of $9.2 million in Q3 2024, worsening from a loss of $6.2 million in Q3 2023.
Operational Challenges Persist: 3. Operational Losses: Loss from operations decreased by $1.5 million, but remained high at $7.3 million for Q3 2024, indicating ongoing operational challenges.
Limited Prescription Growth: 4. Stagnant Prescription Volume: Prescription volume for Mytesi increased by only 2.7% compared to Q3 2023, suggesting limited growth in product uptake.
Sluggish Revenue Growth: 5. Underperformance in Revenue Growth: Total net revenue of approximately $3.1 million in Q3 2024, while an increase from previous quarters, reflects only an 11% rise compared to Q3 2023, indicating sluggish overall revenue growth.
JAGX FAQs
How does JAGX typically perform around its earnings report dates?
Is Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
JAGX Earning Call Sentiment
Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
JAGX.O
7.14%Positive
The earnings call presents a mixed sentiment. The positive highlights include a 14% revenue increase and the launch of Gelclair, but these are offset by a significant EBITDA loss, increased net loss, and risks related to market acceptance, regulatory challenges, and competition. The Q&A reveals uncertainty about partnerships and profitability strategies. Despite optimistic revenue expectations and product development, the financial instability and lack of clear guidance on partnerships lead to a neutral prediction for stock price movement.
